Back to top
more

Harrow, Inc. (HROW)

(Real Time Quote from BATS)

$33.02 USD

33.02
209,313

0.00 (0.00%)

Updated Aug 7, 2025 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Harrow Health (HROW) in Q2 Earnings?

by Zacks Equity Research

Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.

Zacks Equity Research

Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harrow Health (HROW) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Harrow Health (HROW) closed at $8.97, marking a +0.56% move from the previous day.

Zacks Equity Research

Is Harrow Health (HROW) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (HROW) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Harrow (HROW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Avantor, Inc. (AVTR) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Riya Anand headshot

Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market

by Riya Anand

Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.

Zacks Equity Research

Harrow (HROW) Surges 12%: Is This an Indication of Further Gains?

by Zacks Equity Research

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Will Harrow Health (HROW) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

HealthEquity (HQY) Enhances Commuter Offering With New Buyout

by Zacks Equity Research

HealthEquity's (HQY) buyout of Luum will strengthen the former's potential for new hybrid workplace as well as provide safe and affordable commuting options to employees.

Zacks Equity Research

Harrow Health (HROW) Lags Q4 Earnings Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health

by Zacks Equity Research

Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health

Urmimala Biswas headshot

4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis

by Urmimala Biswas

Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Service industry. AMEH, BMXMF, CDNA and HROW are well positioned to gain.

Zacks Equity Research

Harrow Health (HROW) Looks Good: Stock Adds 9.1% in Session

by Zacks Equity Research

Harrow Health (HROW) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

Harrow Health (HROW) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 88.24% and 65.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Harrow Health (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harrow Health (HROW) Enters Oversold Territory

by Zacks Equity Research

Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Equity Research

Harrow Health's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Harrow Health.

Zacks Equity Research

Harrow Health's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Harrow Health.

Zacks Equity Research

Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harrow Health (HROW) in Focus: Stock Moves 6.9% Higher

by Zacks Equity Research

Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?